Micro-X Ltd. · ASX:MX1

Micro-X — Bioshares Biotech Summit 2019

23 slides from Micro-X's conference presentation, Jul 26, 2019

  1. Slide 1: Company Presentation

    Ltd ACN 153 273 735 ASX: MX1 Company Presentation Setting Course & Scaling up commercial activities Bioshares Biotech Summit 2019, Queenstown NZ, 26th July 2019 Peter Rowland Managing Director & CEO

  2. Slide 2: Disclaimer

    Disclaimer This document contains certain forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflected in the forward-looking statements are reasonable at this time, we can give no assurance that these expectations will prove to be correct. Giv

  3. Slide 3: Overview

    Overview Next generation X-ray for global health and security markets • ASX listed hi-tech X-ray company based in Tonsley, Adelaide • Next generation, cold cathode nano technology enables X-ray products with significant reduction in size, weight and power requirements • greater mobility and ease of

  4. Slide 4: Investment Highlights

    Investment Highlights Advanced technology, design and manufacturing company • Platform technology – health and security applications • Built strong Design and Manufacturing capability & processes • Addressed manufacturing issues with CNT insourcing project • First product, DRX Revolution Nano, alrea

  5. Slide 5: Next generation X-ray technology

    Next generation X-ray technology Our carbon nanotube technology provides a revolution in X-ray products & functions Existing X-Ray Technology Next Gen Filament LED Technology unchanged since 1896 CNT emitter + electronic control generates X-ray beam Hot filament generates X-ray beam Up to 10x smalle

  6. Slide 6: Product roadmap

    Product roadmap Planned product evolution – from current X-ray uses to solving unmet needs Mobile medical X-ray Mobile medical X-ray Counter terrorism Airport screening for Military IED Detection Nano Rover MBS MBI Launched 2019 Launch late 2020 Prototype ~ 2021 Prototype end 2020 Healthcare applica

  7. Slide 7: Business model & Strategies

    Business model & Strategies Commercialise our proprietary technology products with selected global partners • Multi-pronged strategy in healthcare, defence and security – based on proprietary technology • World leading in-house design and technology capabilities • Expand highly robust quality manufa

  8. Slide 8: Corporate Snapshot

    Corporate Snapshot Growth stage company with institutional and strategic investor support Share & Trading Statistics (Closing Price on 22 July 2019) Share Price $0.32 per share Total Shares On Issue 158.3 million MX1 - Three month trading $0.40 1.6 Millions Options Issued 13.7 million $0.35 1.4 Conv

  9. Slide 9: Experienced leadership

    Experienced leadership Technical and commercial expertise to support our goals and objectives Peter Rowland Patrick O’Brien Yasmin King Dr Alexander Gosling, AM Managing Director & CEO Non-Executive Chairman Non-Executive Director Non-Executive Director Over 30 years’ hi-tech engineering and Over 25

  10. Slide 10: DRX Revolution Nano

    DRX Revolution Nano Our first commercial product - Healthcare © Micro-X Ltd 2019 Company Presentation – July 2019 10

  11. Slide 11: New solution in mobile X-ray for healthcare

    New solution in mobile X-ray for healthcare Carestream Health is a world leader in mobile X-ray for the healthcare market • Carestream Health Product Overview • FDA approved Class II Medical device appointed global distributor • True mobile X-ray device overcoming limitations of competing mobile X-r

  12. Slide 12: Two year delay - lessons we have learned

    Two year delay - lessons we have learned Commercial teething problems we did not anticipate • Quality / yield and reliability issues • Air freight – resolved with new packaging & procedures • XinRay tube – drove a strategic shift to insource a superior emitter • 2017 X-ray Tube Insourcing Project –

  13. Slide 13: Insourcing & Manufacturing Scale up

    Insourcing & Manufacturing Scale up Next stage Expansion and vertical integration of tube supply Tonsley Facility, Adelaide • > 1,000 m2 • Capacity for medium term needs of Nano production • Dedicated Rover production • Test facilities for MBI project • Mechanical & electrical lab space • Shielded r

  14. Slide 14: Other products in development

    Other products in development Rover and Mobile Backscatter Imager © Micro-X Ltd 2019 Company Presentation – July 2019 14

  15. Slide 15: Rover - Second Product in Development

    Rover - Second Product in Development Mobile X-Ray for NATO Role 2-E Deployed Military Medical Facilities • Armies typically use small Product Overview animal X-ray and Naval vessels • Based on key elements of Nano - FDA approved Class II Medical device use X-ray machines in port • Higher energy X-r

  16. Slide 16: MBI - Third Product in development

    MBI - Third Product in development Unmanned full assessment of potential IEDs • Bomb disposal technicians face life Product Characteris7cs threatening harm when placing X- • Multi-beam CNT imaging with Backscatter detector – enables one-sided X-ray image ray detector behind the IEDs • Thales collabo

  17. Slide 17: Future aviation security concepts

    Future aviation security concepts Next Generation Airport X-Ray screening – ‘high speed’ and ‘self service’ High speed – Airport 3D X-ray conveyor Self service checkpoint X-ray model • Latest ECAC Detection Standards 3 & 4 • Secondary screening at boarding gate • Screen up to 1,200 bags p/h (current

  18. Slide 18: Thales partnership & $10m investment

    Thales partnership & $10m investment Technology partnership with a global leader in defence and aircraft security • $10M investment via convertible loan • $5m cash received July 2019 on completion • Contract design and licensing of Airport Checkpoint Security Imaging • Distribution for MBI in Defenc

  19. Slide 19: Future Product Opportunity

    Future Product Opportunity Brain Perfusion CT Imaging • Golden hour - time to commence stroke treatment biggest factor in patient care Product Characteris7cs • Multi-beam tomography imaging • Ambulances provide first patient contact – need • Ideal to provide early diagnosis of stroke – clot or bleed

  20. Slide 20: Goals & Objectives

    Goals & Objectives We are now setting course © Micro-X Ltd 2019 Company Presentation – July 2019 20

  21. Slide 21: Milestones - setting our new course

    Milestones - setting our new course Focused on delivering commercial outcomes for all stakeholders Early US sales of Nano Thales Partnering deal & $5m CY 2019 CY 2020 Beyond Next Stage Facility expansion CNT in-sourcing complete 1H - Build on Nano sales Significant Rover & Nano sales Q3 – First Nano

  22. Slide 22: Conclusions

    Conclusions Building commercialisation of next generation X-ray technology • Next generation X-ray platform – health and security markets • Significant technology advantages • smaller, lighter, more mobility, new applications • Strategy and focus on technology development & manufacture • Commercial

  23. Slide 23: Peter Rowland

    ACN 153 273 735 Peter Rowland Managing Director 1284 South Road Tonsley SA 5042 +61 8 7099 3966 admin@micro-x.com

Micro-X — Bioshares Biotech Summit 2019 on 6ix